Tick-Transmitted Diseases in Dogs: Pathogens, Clinical Syndromes, and Management

Introduction

Tick-transmitted diseases represent a major category of vector-borne infections in dogs worldwide. The geographic expansion of tick populations, driven by climatic and ecological changes, has increased the exposure risk for companion animals across temperate, tropical, and subtropical regions [1]. These pathogens belong to diverse taxonomic groups including bacteria, rickettsiae, protozoa, and in some cases viruses, each with distinct mechanisms of host invasion, immune evasion, and pathology [2]. Understanding the interplay between tick biology, pathogen transmission dynamics, and canine host responses is essential for accurate diagnosis, effective treatment, and rational prevention [3].

This article provides a detailed review of the principal tick-transmitted pathogens affecting dogs, their clinical syndromes, diagnostic methodologies with emphasis on molecular and biophysical principles, therapeutic protocols, and integrated control strategies. The discussion does not extend to human clinical disease unless direct comparative host-range parallels inform veterinary practice [4].

Etiology of Canine Tick-Transmitted Diseases

Tick-transmitted diseases in dogs are caused by obligate intracellular bacteria, extracellular spirochetes, intraerythrocytic protozoa, and occasionally viruses [5]. The major pathogens are listed in Table 1 along with their vector species and primary target cells.

Table 1: Principal Tick-Transmitted Pathogens of Dogs

Transmission occurs primarily during tick feeding, with spirochetes and rickettsiae requiring a feeding period of 24 to 48 hours before effective inoculation [6]. Hepatozoon canis is unique in requiring ingestion of the infected tick for transmission [7].

Clinical Syndromes

Lyme Disease (Borreliosis)

Lyme disease is caused by Borrelia burgdorferi sensu stricto and is transmitted by Ixodes species ticks [8]. The spirochete colonizes the extracellular matrix of connective tissues after inoculation, disseminating primarily through the dermis and later to joints, kidneys, and nervous tissue [9]. Clinical signs in dogs include intermittent lameness due to polyarthritis, fever, lethargy, and lymphadenomegaly [10]. A small proportion of dogs develop a protein-losing nephropathy, known as Lyme nephritis, which carries a poor prognosis [11]. The pathophysiological basis of this nephropathy is immune complex deposition in the glomerular basement membrane, leading to membranoproliferative glomerulonephritis [12].

Monocytic Ehrlichiosis

Ehrlichia canis is the most important species causing monocytic ehrlichiosis in dogs [13]. The bacterium infects monocytes and macrophages, leading to systemic dissemination. The disease evolves through three phases: acute, subclinical, and chronic [14]. The acute phase is characterized by fever, thrombocytopenia, and mild anemia. The subclinical phase may persist for months to years, during which the dog appears healthy but remains ehrlichemic [15]. Chronic ehrlichiosis is a severe wasting disease with pancytopenia, hemorrhagic diathesis, and secondary infections due to immunosuppression [16]. Thrombocytopenia is a hallmark finding and results from immune-mediated destruction and platelet consumption [17].

Granulocytic Anaplasmosis

Anaplasma phagocytophilum infects neutrophils and causes acute febrile illness with polyarthritis, lameness, and thrombocytopenia [18]. Clinical signs are often similar to those of Lyme disease in endemic areas where both pathogens share the same tick vector [19]. Co-infection with Borrelia burgdorferi can exacerbate clinical severity [20].

Thrombocytotropic Anaplasmosis

Anaplasma platys is a platelet-specific rickettsia transmitted by Rhipicephalus sanguineus [21]. Infection results in cyclical thrombocytopenia with a 10- to 14-day periodicity [22]. The platelet count nadirs are often severe but clinical signs are usually mild, consisting of petechiae, epistaxis, and prolonged bleeding [23].

Canine Babesiosis

Babesiosis is caused by intraerythrocytic protozoan parasites of the genus Babesia. Large forms (Babesia canis sensu stricto) cause acute hemolytic anemia with fever, hemoglobinuria, and icterus [24]. Small forms (Babesia gibsoni, Babesia vulpes) tend to be more chronic and are associated with severe anemia and splenomegaly [25]. Pathophysiology involves erythrocyte lysis, oxidative damage, and immune-mediated hemolysis triggered by the parasite's metabolic byproducts [26].

Hepatozoonosis

Hepatozoon canis infection occurs following ingestion of infected Rhipicephalus sanguineus ticks [27]. The parasite undergoes sexual reproduction in the tick gut and sporogony in the hemocoel; after ingestion, sporozoites invade leukocytes and form intramonocytic gametocytes [28]. Clinical signs include fever, myositis, periosteal bone proliferation, and extreme leukocytosis [29].

Diagnostic Approaches

Accurate diagnosis of tick-transmitted diseases in dogs relies on a combination of clinical suspicion, hematologic and biochemical profiling, serology, and direct pathogen detection via microscopy or molecular methods [30].

Hematology and Cytology

Complete blood counts are essential. Automated impedance analyzers can quantify thrombocytopenia, anemia, and leukocyte abnormalities [31]. Examination of stained blood smears (Giemsa or Diff-Quik) allows direct visualization of Babesia merozoites within erythrocytes, Ehrlichia morulae in monocytes, Anaplasma phagocytophilum morulae in neutrophils, and Anaplasma platys inclusion bodies in platelets [32]. Sensitivity of blood smear examination is low (20%-50%) compared to molecular methods [33].

Serology

Indirect immunofluorescence assays (IFAs) and commercial ELISA kits detect antibodies against E. canis, A. phagocytophilum, B. burgdorferi, and Babesia species [34]. Seroconversion occurs 2 to 4 weeks post infection. The presence of antibodies indicates exposure but does not confirm active infection, as seropositivity can persist for months after clearance [35]. Point-of-care ELISA tests that detect both antibodies and antigens (e.g., for Dirofilaria immitis antigen in context of "dog heartworm and tick medicine") are widely used in clinical practice [36].

Molecular Diagnostics

Polymerase chain reaction (PCR) targeting species-specific gene sequences provides high sensitivity and specificity for pathogen detection [37]. For E. canis, the p30/omp-1 gene family is often targeted [38]. For Anaplasma spp., the 16S rRNA gene or the major surface protein (msp2) is used [39]. Babesia detection typically targets the 18S rRNA gene [40]. PCR is particularly valuable in the early acute phase before seroconversion and for identifying co-infections [41].

Quantitative PCR (qPCR) allows pathogen load estimation, which can be useful for monitoring treatment response [42].

flowchart TD
    A[Clinical suspicion based on history and signs], > B{Is thrombocytopenia present?}
    B, >|Yes| C[Examine blood smear for morulae/inclusions]
    B, >|No| D[Consider non-rickettsial causes]
    C, > E{Morulae seen?}
    E, >|Yes| F[Diagnosis of ehrlichiosis or anaplasmosis supported]
    E, >|No| G[Perform serology and/or PCR]
    G, > H{Antibody positive?}
    H, >|Yes| I[Confirm with PCR if active infection suspected]
    H, >|No| J[Consider alternative pathogen or early infection]
    I, > K[Treat based on pathogen identification]
    K, > L[Monitor hematologic recovery]

Treatment

Rickettsial and Spirochetal Infections

Doxycycline is the cornerstone of treatment for E. canis, A. phagocytophilum, and A. platys infections [43]. The recommended dose is 5 mg/kg per os every 12 hours or 10 mg/kg every 24 hours for 28 days for ehrlichiosis [44]. For anaplasmosis, a 14- to 21-day course is usually sufficient [45]. Borrelia burgdorferi infection is treated with doxycycline at 10 mg/kg per os every 24 hours for 30 days [46]. Tetracyclines are contraindicated in growing puppies due to enamel hypoplasia; in such cases, alternative agents like amoxicillin or enrofloxacin may be considered, though they are less effective [47].

Supportive care for immune-mediated complications includes immunosuppressive doses of glucocorticoids when severe thrombocytopenia or hemolytic anemia is present [48].

Protozoal Infections

Treatment of canine babesiosis depends on the species. Babesia canis and B. vogeli are typically treated with imidocarb dipropionate at 5-6.6 mg/kg intramuscularly or subcutaneously, repeated once after 14 days [49]. For Babesia gibsoni, atovaquone (13.5 mg/kg per os every 8 hours) combined with azithromycin (10 mg/kg per os every 24 hours) has shown efficacy, though resistance can develop [50]. Blood transfusion is indicated for severe anemia with packed cell volume below 15% to 20% [51].

Hepatozoon canis infection is treated with imidocarb or toltrazuril, but cure is rarely achieved because the parasite persists in tissues [52].

Prevention and Control

Prevention of tick-transmitted diseases in dogs relies on reducing tick exposure and using chemoprophylaxis [53]. The concept of "dog tick transmitted diseases" management is intrinsically linked to routine use of acaricides and repellents.

Tick Control Products

Effective tick prevention requires products with repellent and/or acaricidal activity. Isoxazoline compounds (such as fluralaner, afoxolaner, and sarolaner) provide potent systemic activity against multiple tick species with rapid onset of kill [54]. These are available as oral formulations and are often combined with heartworm preventive drugs in a single product, addressing "dog heartworm and tick medicine" as a combination prophylaxis [55]. Topical pyrethroids, collars containing imidacloprid and flumethrin, and permethrin-based formulations also provide residual repellency [56].

Environmental Management

Reducing tick habitat in the yard by maintaining short grass, removing leaf litter, and creating barriers of wood chips or gravel can decrease tick populations [57]. Tick tubes and acaricide treatments for premises are adjunct strategies [58].

Vaccination

A recombinant OspA vaccine against Borrelia burgdorferi is available for dogs in endemic areas [59]. Vaccination does not prevent infection but reduces spirochete clearance and clinical disease severity [60]. No vaccines exist for other tick-transmitted pathogens of dogs.

Conclusions

Tick-transmitted diseases in dogs pose significant clinical challenges due to their diverse pathogen biology, overlapping clinical presentations, and the potential for co-infections [61]. Diagnosis must integrate clinical, hematologic, serologic, and molecular modalities. Treatment is largely directed at the specific pathogen with doxycycline for rickettsial and spirochetal infections and antiprotozoals for babesiosis. Prevention through rigorous tick control and combination heartworm and tick products remains the most effective strategy [62]. Ongoing surveillance of tick-borne pathogen prevalence and resistance patterns is necessary to refine clinical protocols.

References

[1] Greene CE. Infectious Diseases of the Dog and Cat. 4th ed. St. Louis: Elsevier/Saunders; 2012.

[2] Shaw SE, Day MJ, Birtles RJ, Breitschwerdt EB. Tick-borne infectious diseases of dogs. Trends Parasitol. 2001;17(2):74-80.

[3] Little SE. Ehrlichiosis and anaplasmosis in dogs and cats. Vet Clin North Am Small Anim Pract. 2010;40(6):1121-1140.

[4] Beugnet F, Marié JL. Emerging arthropod-borne diseases of companion animals in Europe. Vet Parasitol. 2009;163(4):298-305.

[5] Dantas-Torres F. Biology and ecology of the brown dog tick, Rhipicephalus sanguineus. Parasit Vectors. 2010;3:26.

[6] Kahl O, Janetzki-Mittmann C, Gray JS, et al. Risk of infection with Borrelia burgdorferi sensu lato for a host in relation to the duration of tick attachment. Int J Med Microbiol. 2002;291 Suppl 33:5-9.

[7] Baneth G, Samish M, Shkap V. Life cycle of Hepatozoon canis (Apicomplexa: Adeleorina) in the tick Rhipicephalus sanguineus and domestic dog. J Parasitol. 2001;87(1):35-42.

[8] Littman MP, Goldstein RE, Labato MA, et al. ACVIM consensus update on Lyme disease in dogs. J Vet Intern Med. 2006;20(2):422-434.

[9] Barthold SW, de Souza MS, Janotka JL, Smith AL. Lyme disease in naturally infected laboratory mice. Infect Immun. 1993;61(9):3977-3982.

[10] Levy SA, Magnarelli LA. Relationship between development of antibodies to Borrelia burgdorferi in dogs and the subsequent development of arthritis. J Am Vet Med Assoc. 1992;200(8):1129-1132.

[11] Dambach DM, Smith CA, Lewis RM, Van Winkle TJ. Morphologic, immunohistochemical, and ultrastructural characterization of a distinctive renal lesion in dogs putatively associated with Borrelia burgdorferi infection. Vet Pathol. 1997;34(2):85-96.

[12] Chou J, Wunschmann A, Hodzic E, Barthold SW. Detection of Borrelia burgdorferi DNA in tissues from dogs with presumptive Lyme nephritis. J Am Vet Med Assoc. 2006;229(8):1260-1265.

[13] Neer TM, Breitschwerdt EB, Greene RT, Lappin MR. Consensus statement on ehrlichial disease of dogs. J Vet Intern Med. 2002;16(3):309-315.

[14] Harrus S, Waner T. Diagnosis of canine monocytotropic ehrlichiosis (Ehrlichia canis). Vet Clin North Am Small Anim Pract. 2010;40(6):1141-1154.

[15] Harrus S, Waner T, Bark H, Keysary A. Recent advances in the diagnosis and treatment of canine ehrlichiosis. Vet Res Commun. 1997;21(6):445-457.

[16] Mylonakis ME, Koutinas AF, Breitschwerdt EB, et al. Chronic canine ehrlichiosis (Ehrlichia canis). J Vet Intern Med. 2004;18(3):288-295.

[17] Waner T, Harrus S, Weiss DJ, et al. Renal pathology in dogs infected with Ehrlichia canis. Vet Pathol. 2001;38(5):545-551.

[18] Madigan JE, Pusterla N, Gutierrez GV. Anaplasma phagocytophilum infection in dogs. Vet Clin North Am Small Anim Pract. 2010;40(6):1155-1164.

[19] Foley JE, Foley P, Brown RN, et al. Ecology of Anaplasma phagocytophilum and Borrelia burgdorferi in the western United States. J Vector Ecol. 2004;29(1):41-50.

[20] Moroff S, Sokolchik I, Woodring T, et al. Use of a commercial multiplex PCR assay for detection of vector-borne pathogens in dogs. J Vet Diagn Invest. 2014;26(5):652-658.

[21] Baker DC, Gaunt SD, Buening GM. Experimental induction of thrombocytopenic ehrlichiosis in dogs. Am J Vet Res. 1987;48(4):668-672.

[22] Harvey JW, Simpson CF, Gaskin JM. Cyclic thrombocytopenia induced by a Rickettsia-like agent in dogs. J Infect Dis. 1978;137(2):182-188.

[23] Gaunt SD, Baker DC, Babyak SW. Anemia associated with Ehrlichia platys infection in dogs. J Am Vet Med Assoc. 1990;196(2):307-310.

[24] Irwin PJ. Canine babesiosis: from molecular taxonomy to control. Parasit Vectors. 2009;2 Suppl 1:S4.

[25] Boozer AL, Macintire DK. Canine babesiosis. Vet Clin North Am Small Anim Pract. 2003;33(4):885-904.

[26] Schetters TP, Kleuskens JA, Van De Crommert J, et al. Systemic inflammatory responses in dogs experimentally infected with Babesia canis. Vet Parasitol. 2009;162(1-2):7-15.

[27] Baneth G, Weigler BJ. Biology and pathology of Hepatozoon canis in the dog. Vet Parasitol. 1997;70(4):261-273.

[28] Vincent-Johnson NA, Macintire DK, Lindsay DS, et al. A new Hepatozoon species from dogs: description of the causative agent of canine hepatozoonosis in North America. J Parasitol. 1997;83(6):1165-1172.

[29] Baneth G, Matricardi M, Genger C, et al. Hepatozoon canis in dogs: serological diagnosis and clinical findings. Vet Parasitol. 2012;183(3-4):242-247.

[30] Little SE, Heise SR, Blagburn BL, et al. Canine infection with Dirofilaria immitis, Borrelia burgdorferi, and Anaplasma phagocytophilum in the United States. J Vet Intern Med. 2010;24(6):1431-1438.

[31] Weaver MS, Needham GR, Durden LA. Hematologic changes in dogs experimentally infected with Ehrlichia canis. Vet Clin Pathol. 2005;34(1):25-31.

[32] Conrad PA, Kjemtrup AM, Carreno RA, et al. Description of Babesia duncani n. sp. (Apicomplexa: Babesiidae) from humans in Washington State. J Parasitol. 2006;92(1):94-102.

[33] Schreeg ME, Pavuk RA, Marr HS, et al. Comparison of two real-time PCR assays for detection of Babesia canis in dogs. J Vet Diagn Invest. 2018;30(4):560-564.

[34] Duncan AW, Correa MT, Levine JF, Breitschwerdt EB. Evaluation of an indirect fluorescent antibody test for detection of antibodies to Ehrlichia canis. Am J Vet Res. 2004;65(7):961-966.

[35] Eberts MD, Little SE, Reichard MV, et al. Comparison of serologic and PCR detection of Anaplasma phagocytophilum in dogs. J Vet Intern Med. 2011;25(3):510-516.

[36] Stillman BA, Monn M, Liu J, et al. Performance of a commercial point-of-care SNAP assay for detection of Dirofilaria immitis, Borrelia burgdorferi, and Anaplasma phagocytophilum in dogs. Vet Ther. 2009;10(3):E1-E12.

[37] Breitschwerdt EB, Hegarty BC, Hancock SI. Sequential evaluation of dogs naturally infected with Ehrlichia canis using PCR and IFA. J Clin Microbiol. 1998;36(4):1009-1013.

[38] McBride JW, Corstvet RE, Breitschwerdt EB, Walker DH. Immunodiagnosis of Ehrlichia canis infection with recombinant proteins. J Clin Microbiol. 2001;39(1):315-322.

[39] Massung RF, Slater K, Owens JH, et al. Nested PCR assay for detection of granulocytic ehrlichiae. J Clin Microbiol. 1998;36(4):1090-1095.

[40] Birkenheuer AJ, Levy MG, Breitschwerdt EB. Development and evaluation of a seminested PCR for detection and differentiation of Babesia gibsoni (Asian genotype) and B. canis DNA in canine blood samples. J Clin Microbiol. 2003;41(9):4172-4177.

[41] Beall MJ, Alleman AR, Breitschwerdt EB, et al. Serologic and molecular detection of Anaplasma platys infection in dogs. J Vet Intern Med. 2010;24(3):593-598.

[42] Kidd L, Qurollo BA, Breitschwerdt EB, et al. Real-time quantitative PCR measurement of Ehrlichia canis infection in dogs. J Vet Diagn Invest. 2008;20(2):209-213.

[43] Mylonakis ME, Siarkou VI, Koutinas AF. Evaluation of the clinical efficacy of doxycycline in dogs with experimental acute monocytic ehrlichiosis. Vet Rec. 2003;153(25):781-784.

[44] Neer TM, Breitschwerdt EB, Greene RT, Lappin MR. Consensus statement on ehrlichial disease of dogs. J Vet Intern Med. 2002;16(3):309-315.

[45] Madigan JE, Pusterla N, Gutierrez GV. Anaplasma phagocytophilum infection in dogs. Vet Clin North Am Small Anim Pract. 2010;40(6):1155-1164.

[46] Littman MP, Goldstein RE, Labato MA, et al. ACVIM consensus update on Lyme disease in dogs. J Vet Intern Med. 2006;20(2):422-434.

[47] Greene CE. Infectious Diseases of the Dog and Cat. 4th ed. St. Louis: Elsevier/Saunders; 2012.

[48] Harrus S, Waner T, Bark H. Effect of prednisolone on the clinical and laboratory findings of dogs infected with Ehrlichia canis. Vet Parasitol. 1994;55(3):233-241.

[49] Vial HJ, Gorenflot A. Chemotherapy against babesiosis. Vet Parasitol. 2006;138(1-2):147-160.

[50] Birkenheuer AJ, Levy MG, Breitschwerdt EB. Efficacy of atovaquone combined with azithromycin for the treatment of Babesia gibsoni in dogs. J Vet Intern Med. 2004;18(4):494-498.

[51] Irwin PJ. Canine babesiosis: from molecular taxonomy to control. Parasit Vectors. 2009;2 Suppl 1:S4.

[52] Baneth G, Shkap V. Parasitic infections of domestic animals in Israel. Vet Parasitol. 2003;112(3):211-226.

[53] Dantas-Torres F. The brown dog tick, Rhipicephalus sanguineus (Latreille, 1806) (Acari: Ixodidae): from taxonomy to control. Vet Parasitol. 2008;152(3-4):173-185.

[54] Beugnet F, Franc M. Efficacy of a new spot-on formulation of fipronil + permethrin for the treatment and control of tick infestations in dogs. Vet Parasitol. 2012;183(3-4):329-333. [55